Neulasta® (pegfilgrastim) is a drug given to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta is given as a single subcutaneous injection of 6 mg administered once per chemotherapy cycle in adults. It was approved by the FDA in January 2002. Neulasta is an example of a drug that uses a polymer–protein conjugate nanocarrier and Nektar's PEGylation Technology™ is used in Neulasta.

Product Released: 
January, 2002
Information Verified: 
October, 2013

Californa Locations:

Displaying 1 - 1 of 1